6 Years Later, 9-Valent HPV Vaccine's Efficacy Persists

The quadrivalent human papillomavirus (qHPV) vaccine has a population-level beneficial effect on cervical high-grade lesions and genital warts caused by HPV 16, 18, 6, and 11, but misses some 30% of disease attributable to other HPV types. The 9-valent (9v) HPV vaccine provides additional protection against HPV types 31, 35, 45, 52, and 58. Investigators now report the final results of an international, manufacturer-funded clinical trial in which >14,000 women (age range, 16–26) were randomized to receive three doses of either qHPV or 9vHPV vaccine and followed for up to 6 years.

Among women who received the 9vHPV vaccine, incidence of cervical, vaginal, and vulvar disease related to the five additional HPV types was reduced by 97% compared …